Arvest Trust’s Bristol-Myers Squibb BMY Stock Holding History

Arvest Trust’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1.47M	Sell	35,482 -2,691	-7%	-$120K	0.09%	95
2024 Q1	$2.07M	Buy	38,173 +3,275	+9%	+$167K	0.12%	91
2023 Q4	$1.79M	Sell	34,898 -8,854	-20%	-$465K	0.11%	93
2023 Q3	$2.54M	Sell	43,752 -683	-2%	-$41.8K	0.17%	73
2023 Q2	$2.76M	Sell	44,435 -3,139	-7%	-$210K	0.16%	72
2023 Q1	$3.3M	Buy	47,574 +3,599	+8%	+$254K	0.21%	68
2022 Q4	$3.16M	Buy	43,975 +3,497	+9%	+$264K	0.2%	66
2022 Q3	$2.88M	Buy	40,478 +14,324	+55%	+$1.04M	0.2%	65
2022 Q2	$2.01M	Sell	26,154 -2,273	-8%	-$173K	0.13%	69
2022 Q1	$2.08M	Buy	28,427 +13,216	+87%	+$887K	0.12%	68
2021 Q4	$948K	Buy	+15,211	New	+$892K	0.05%	97

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arvest Trust's BMY Position: Q2 2024 in Review

Arvest Trust reduced its Bristol-Myers Squibb (BMY) stake by 7% in Q2 2024, selling an estimated $120K and leaving 35,482 shares worth $1.47M. The position accounts for 0.09% of the portfolio, ranked #95.

Arvest Trust first reported a position in BMY in Q4 2021 and has held it in 11 quarters since. The position peaked at $3.3M in Q1 2023. 2,148 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Arvest Trust held 35,482 shares of Bristol-Myers Squibb worth $1.47M as of Q2 2024.
Arvest Trust sold 2,691 Bristol-Myers Squibb shares in Q2 2024, an estimated $120K.
Bristol-Myers Squibb made up 0.09% of Arvest Trust's portfolio in Q2 2024, its #95 holding.
Arvest Trust first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 11 quarters since.
Arvest Trust's Bristol-Myers Squibb position peaked at $3.3M in Q1 2023.
2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Arvest Trust's 13F filing for Q2 2024, filed 9 Aug 2024.